4-Bromo-2,5-dimethoxyamphetamine
Identification
- Generic Name
- 4-Bromo-2,5-dimethoxyamphetamine
- DrugBank Accession Number
- DB01484
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental, Illicit
- Structure
Structure for 4-Bromo-2,5-dimethoxyamphetamine (DB01484)
- Weight
- Average: 274.154
Monoisotopic: 273.036441408 - Chemical Formula
- C11H16BrNO2
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with 1,2-Benzodiazepine. Abaloparatide The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Abaloparatide. Acebutolol The therapeutic efficacy of Acebutolol can be decreased when used in combination with 4-Bromo-2,5-dimethoxyamphetamine. Aceclofenac The risk or severity of hypertension can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Aceclofenac. Acemetacin The risk or severity of hypertension can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Acemetacin. Acenocoumarol The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Acenocoumarol. Acetazolamide Acetazolamide may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level. Acetophenazine Acetophenazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine. Acetylsalicylic acid The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with 4-Bromo-2,5-dimethoxyamphetamine. Aclidinium 4-Bromo-2,5-dimethoxyamphetamine may increase the central nervous system depressant (CNS depressant) activities of Aclidinium. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Agents producing tachycardia
- Agents that produce hypertension
- Amines
- Amphetamines
- Antidepressive Agents
- Central Nervous System Agents
- Central Nervous System Depressants
- Ethylamines
- Hallucinogens
- Neurotransmitter Agents
- Phenethylamines
- Psychotropic Drugs
- Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
- Serotonin Agents
- Serotonin Receptor Agonists
- Sympathomimetics
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Phenethylamines
- Direct Parent
- Amphetamines and derivatives
- Alternative Parents
- Dimethoxybenzenes / Phenylpropanes / Phenoxy compounds / Anisoles / Bromobenzenes / Aralkylamines / Alkyl aryl ethers / Aryl bromides / Organopnictogen compounds / Organobromides show 2 more
- Substituents
- Alkyl aryl ether / Amine / Amphetamine or derivatives / Anisole / Aralkylamine / Aromatic homomonocyclic compound / Aryl bromide / Aryl halide / Bromobenzene / Dimethoxybenzene show 17 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 67WJC4Y2QY
- CAS number
- 32156-26-6
- InChI Key
- FXMWUTGUCAKGQL-UHFFFAOYSA-N
- InChI
- InChI=1S/C11H16BrNO2/c1-7(13)4-8-5-11(15-3)9(12)6-10(8)14-2/h5-7H,4,13H2,1-3H3
- IUPAC Name
- 1-(4-bromo-2,5-dimethoxyphenyl)propan-2-amine
- SMILES
- COC1=CC(Br)=C(OC)C=C1CC(C)N
References
- General References
- Not Available
- External Links
- PubChem Compound
- 62065
- PubChem Substance
- 46507989
- ChemSpider
- 55902
- BindingDB
- 50005257
- ChEMBL
- CHEMBL6607
- Guide to Pharmacology
- GtP Drug Page
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source logP 2.58 HANSCH,C & LEO,AJ (1985) - Predicted Properties
Property Value Source Water Solubility 0.0948 mg/mL ALOGPS logP 2.53 ALOGPS logP 2.26 ChemAxon logS -3.5 ALOGPS pKa (Strongest Basic) 9.9 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 44.48 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 64.25 m3·mol-1 ChemAxon Polarizability 25.28 Å3 ChemAxon Number of Rings 1 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9962 Blood Brain Barrier + 0.9475 Caco-2 permeable + 0.7137 P-glycoprotein substrate Non-substrate 0.711 P-glycoprotein inhibitor I Non-inhibitor 0.804 P-glycoprotein inhibitor II Non-inhibitor 0.9441 Renal organic cation transporter Non-inhibitor 0.8015 CYP450 2C9 substrate Non-substrate 0.8693 CYP450 2D6 substrate Substrate 0.6261 CYP450 3A4 substrate Substrate 0.5248 CYP450 1A2 substrate Inhibitor 0.8743 CYP450 2C9 inhibitor Non-inhibitor 0.8389 CYP450 2D6 inhibitor Inhibitor 0.8451 CYP450 2C19 inhibitor Non-inhibitor 0.7714 CYP450 3A4 inhibitor Non-inhibitor 0.7737 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.5 Ames test Non AMES toxic 0.5865 Carcinogenicity Non-carcinogens 0.7668 Biodegradation Not ready biodegradable 0.9808 Rat acute toxicity 3.0047 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8956 hERG inhibition (predictor II) Non-inhibitor 0.617
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created on July 31, 2007 13:09 / Updated on June 12, 2020 16:51